$AKTX News

Last published 10h ago

10h agoAKTXAkari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-HoGlobeNewswireDiscussion highlights Vat-Ho’s oncology business development experience, his decision to join Akari and the potential of the Company’s novel PH1 payload platform
1w agoAKTXAkari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload SummitGlobeNewswirePresentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation Satyajit Mitra, Executive Director, Head of Oncology, to
3w agoAKTXAkari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO CornerGlobeNewswireCEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical development in mid-2027 Recent deal activity and emerging
4w agoAKTXAkari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and PartneringGlobeNewswireMr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value Mr. Vat-Ho brings
2mo agoAKTXAkari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare ForumsGlobeNewswireCompany invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote and featured
2mo agoAKTXAkari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand ConferenceGlobeNewswireVideo webcast now available here TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with
2mo agoAIM AKTX CNSP DARE+5JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsACCESS NewswireNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming
2mo agoAKTXAkari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC StrategyGlobeNewswireAKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating payload to overcome
3mo agoAKTXAkari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload PlatformGlobeNewswireAKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated
3mo agoAKTXAkari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC InnovationGlobeNewswireDiscussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform
3mo agoAKTXAkari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology OpportunityGlobeNewswireVirtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform Watch the "What
3mo agoAKTXAkari Therapeutics Enters Strategic Research Collaboration with Whitehawk TherapeuticsGlobeNewswireTAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads,
4mo agoAKTXAkari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory BoardGlobeNewswireGlobally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future
4mo agoAKTXAkari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory MilestonesGlobeNewswireTAMPA, Fla. and LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads,
5mo agoAKTXAkari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026GlobeNewswireDiscussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential Access the Akari CEO Corner here TAMPA, Fla. and LONDON, June 04, 2026 (GLOBE
5mo agoAKTXAkari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor "What This Means" Segment Following ASCO Abstract AcceptanceGlobeNewswireCEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the "What This Means" video here TAMPA, Fla. and LONDON, May 28, 2026 (GLOBE
5mo agoAKTXAkari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer ModelsGlobeNewswireAn ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer modelsData supports the broader
5mo agoAKTXAkari Therapeutics Announces $5.5 Million Private Placement OfferingGlobeNewswireTAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload,
5mo agoAKTXAkari Therapeutics to Present at A.G.P.'s Annual Healthcare Company ShowcaseGlobeNewswireLive webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here TAMPA, Fla. and LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- Akari
6mo agoAKTXAkari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global MarketsGlobeNewswireTAMPA, Fla. and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads,
6mo agoAKTXAkari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC PayloadGlobeNewswirePatent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancerApproval strengthens Akari's global intellectual property across all major markets
6mo agoAKTXAkari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant TumorsGlobeNewswireExpands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:00 PM ET TAMPA,
6mo agoAKTXAkari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA SplicingGlobeNewswireSuperior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance
7mo agoAKTXAkari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDCGlobeNewswireCEO Abizer Gaslightwala discusses the Company's strategic partnership with WuXi XDC and its implications for platform validation and development acceleration Company highlights accelerated IND timeline for AKTX-101 and
7mo agoAKTXAkari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA SplicingGlobeNewswireTAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads
8mo agoAKTXAkari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer GaslightwalaGlobeNewswireHighlights strategic progress achieved under Abizer Gaslightwala's leadership, including advancement of AKTX-101 and expansion of Akari's ADC pipeline Access the Akari CEO Corner here TAMPA, Fla. and LONDON, March
8mo agoAKTXAkari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory BoardGlobeNewswireTAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today
8mo agoAKTXAkari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory BoardGlobeNewswireTAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today
8mo agoAKTXAkari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor ConferenceGlobeNewswireTAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today
9mo agoAKTXAkari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing the Company's Expanded ADC PipelineGlobeNewswireCEO Abizer Gaslightwala discusses the Company's recent announcement around its ADC pipeline expansion and IP strategy Company also discusses its lead ADC program, AKTX-101, and its planned IND and CTA submissions as
9mo agoAIM AKTX BULL DCOY+2JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026ACCESS NewswireRegister for the two-day virtual event hereFRENCHTOWN, NJ / ACCESS Newswire / February 9, 2026 / JTC Team , a fully integrated corporate communications and investor relations firm, today announced its companies
9mo agoAKTXAkari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialGlobeNewswire– Live video webcast on Tuesday, February 10th at 1:00 PM EST TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering
9mo agoAKTXAkari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid TumorsGlobeNewswireCompany expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct to address one of
10mo agoAKTXAkari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026GlobeNewswireAccess the Akari CEO Corner here TAMPA, Fla. and LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug
10mo agoAKTXAkari Therapeutics to Present at the 2026 Biotech ShowcaseGlobeNewswireIn-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari's ADC platform, strategic priorities and key milestones for 2026 TAMPA, Fla.
10mo agoAKTXAkari Therapeutics Issues 2025 End of Year Letter to ShareholdersGlobeNewswireTAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the
10mo agoAKTXAkari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical TrialGlobeNewswireTAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced the
10mo agoAKTXAkari Therapeutics Releases Virtual Investor "What This Means" SegmentGlobeNewswireWatch the "What This Means" video here TAMPA, Fla. and LONDON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug
11mo agoAKTXAkari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-MarketGlobeNewswireTAMPA, Fla. and LONDON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (the "Company"), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today
11mo agoAKTXAkari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic CancerGlobeNewswireData highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates The
11mo agoAKTXAkari Therapeutics Announces Release of the Next CEO Corner SegmentGlobeNewswireAccess the Akari CEO Corner here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates
11mo agoAKTXAkari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial OfficerGlobeNewswireTAMPA and LONDON, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the
1y agoAKTXAkari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint InhibitorsGlobeNewswireData presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor
1y agoAKTXAkari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now AvailableGlobeNewswireBOSTON and LONDON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced its abstract
1y agoAKTXAkari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACPGlobeNewswireBOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the formation of
1y agoAKTXAkari Therapeutics Announces Launch of CEO Corner PlatformGlobeNewswireCEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for future videos Access
1y agoAKTXAkari Therapeutics Announces $2.5 Million Registered Direct OfferingGlobeNewswireBOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (the "Company"), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced
1y agoAKTXAkari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1GlobeNewswireBOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed
1y agoAKTXAkari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) MeetingGlobeNewswireBOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has
1y agoAKTXAkari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1GlobeNewswireData highlights ability of Akari's ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies have proven to be